Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission

C. Lenarsky, K. Weinberg, J. Petersen, Jan Nolta, J. Brooks, G. Annett, D. Kohn, R. Parkman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.

Original languageEnglish (US)
Pages (from-to)425-429
Number of pages5
JournalBone Marrow Transplantation
Volume6
Issue number6
StatePublished - 1990
Externally publishedYes

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Disease-Free Survival
Busulfan
Cyclophosphamide
Survivors
4-hydroxyperoxycyclophosphamide
Transplantation
Erythrocytes
Pediatrics
Transplants
Survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission. / Lenarsky, C.; Weinberg, K.; Petersen, J.; Nolta, Jan; Brooks, J.; Annett, G.; Kohn, D.; Parkman, R.

In: Bone Marrow Transplantation, Vol. 6, No. 6, 1990, p. 425-429.

Research output: Contribution to journalArticle

Lenarsky, C. ; Weinberg, K. ; Petersen, J. ; Nolta, Jan ; Brooks, J. ; Annett, G. ; Kohn, D. ; Parkman, R. / Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission. In: Bone Marrow Transplantation. 1990 ; Vol. 6, No. 6. pp. 425-429.
@article{559036414a1f436a9204c9273f975494,
title = "Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission",
abstract = "Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61{\%}. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.",
author = "C. Lenarsky and K. Weinberg and J. Petersen and Jan Nolta and J. Brooks and G. Annett and D. Kohn and R. Parkman",
year = "1990",
language = "English (US)",
volume = "6",
pages = "425--429",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission

AU - Lenarsky, C.

AU - Weinberg, K.

AU - Petersen, J.

AU - Nolta, Jan

AU - Brooks, J.

AU - Annett, G.

AU - Kohn, D.

AU - Parkman, R.

PY - 1990

Y1 - 1990

N2 - Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.

AB - Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroxyperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the antileukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.

UR - http://www.scopus.com/inward/record.url?scp=0025688660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025688660&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 425

EP - 429

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -